ECS Botanics is launching a range of GMP-certified cannabidiol (CBD) and tetrahydrocannabinol (THC) pastilles and vapes.
The products are expected to be in the market before the end of this year and will increase ECS Botanics' white-label offering to four products - flowers, oils, pastilles and vapes.
Managing Director Nan-Maree Schoerie said, "the expansion of our B2B product range to include GMP-certified CBD and THC pastilles and THC vapes provides our customers and their patients with alternative dosage methods.
"Pastilles and vapes are relatively new delivery methods and will complement our existing B2B offering, leveraging our expertise to meet growing consumer demand for premium medicinal cannabis solutions.
"We have already received pre-orders for these new products and expect demand to increase rapidly," Schoerie commented.
The pastilles will be available in both CBD and THC forms, as well as combinations of both.
They are sugar-free, plant-based, and offered in a range of flavours and colours.
Pastilles are chewed and dissolved in the mouth, enabling the active ingredients to rapidly enter the bloodstream.
The THC distillate vape will be infused with additional terpenes, replacing the previous dried flower vaporiser cartridge product that ECS was looking to introduce to the market in 2023.
The cartridges will be available in 0.5ml and 1ml strengths.
Australian-made, the vape cartridges use oil concentrates manufactured from ECS' pharmaceutical-grade extracts derived from the company's Australian-grown flower, and come in child-resistant packaging, the company statement explained.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Nov 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Nov 23
